Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2005 (53-week fiscal year)
Business Overview: Henry Schein is the largest distributor of healthcare products and services to office-based practitioners in North America and Europe. The company operates through two reportable segments: Healthcare Distribution (dental, medical, veterinary, and international) and Technology (practice management software and value-added services). It serves over 500,000 customers worldwide with operations in 17 countries outside North America.
Key Financial Metrics
| Metric | 2005 | 2004 | Change |
|---|---|---|---|
| Net Sales | $4,635.9 million | $3,898.5 million | +18.9% |
| Gross Profit | $1,316.9 million | $1,054.5 million | +24.9% |
| Gross Margin | 28.4% | 27.0% | +140 bps |
| Operating Income | $281.1 million | $209.8 million | +34.0% |
| Net Income | $151.3 million | $128.2 million | +18.1% |
| Diluted EPS | $1.70 | $1.43 | +18.9% |
| Operating Cash Flow | $265.1 million | $191.0 million | +38.8% |
| Total Assets | $2,583.1 million | $2,433.7 million | +6.1% |
| Total Debt | $524.6 million | $535.6 million | -2.1% |
| Working Capital | $860.3 million | $736.8 million | +16.8% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 18.9% driven by 18.8% local currency growth (8.4% organic, 10.4% from acquisitions) and minimal foreign currency impact. International sales surged 35.4% primarily due to the Demedis Group acquisition.
- Margin Expansion: Gross margin improved to 28.4% from 27.0%. This was largely due to the absence of the low-margin Fluvirin influenza vaccine in 2004 (which caused a $13.2M charge in 2004) and a strategic shift away from lower-margin pharmaceutical products in the medical segment.
- Discontinued Operations: The company decided to divest its Hospital Supply Business in Q3 2005. This resulted in a $11.9 million pre-tax impairment charge ($7.0 million after-tax) and a reclassification of the business as discontinued operations.
- Acquisitions: Significant acquisitions included Ash Temple Limited (Canada) and the Demedis Group (Europe), contributing significantly to revenue and goodwill increases.
Guidance, Outlook, Risks, and Unusual Items
- Divestiture: In March 2006, the company entered an agreement to sell the Hospital Supply Business for $40.0 million. A loss on disposal of $21.0–$24.0 million is expected upon closing.
- Capital Allocation: The company authorized an additional $100.0 million for stock repurchases in October 2005. As of year-end, $88.5 million had been repurchased, with $111.5 million remaining available.
- Capital Expenditures: Expected to invest approximately $67.0 million in 2006 for facility modernization and a new distribution center in France.
- Key Risks:
- Regulatory: Extensive government regulation regarding pharmaceutical distribution, fraud, and abuse laws.
- Competition: Highly competitive market with pressure from manufacturers selling directly to end-users.
- Supply Chain: Dependence on third-party suppliers; risk of product recalls or counterfeit products.
- Interest Rates: Exposure to variable interest rates on $230.0 million of senior notes via swap agreements.
- Unusual Items: The 2004 results were impacted by a $13.2 million charge related to the Chiron Fluvirin contract. The 2005 results include the aforementioned impairment charge for the discontinued Hospital Supply Business.
Investor Verification Checklist
- Discontinued Operations: Verify the final closing terms and actual loss on the sale of the Hospital Supply Business.
- Acquisition Integration: Assess the integration progress and synergy realization from the Demedis Group and Ash Temple acquisitions.
- Stock Repurchase Program: Monitor the execution of the remaining $111.5 million repurchase authorization.
- Regulatory Compliance: Review any updates on FDA approvals for influenza vaccine distribution and compliance with healthcare fraud regulations.
- Debt Structure: Confirm the status of the $240.0 million convertible debt and the impact of interest rate fluctuations on the $230.0 million senior notes.